The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives

Christopher J. Weber, Maria C. Carrillo, William Jagust, Clifford R. Jack, Leslie M. Shaw, John Q. Trojanowski, Andrew J. Saykin, Laurel A. Beckett, Cyrille Sur, Naren P. Rao, Patricio Chrem Mendez, Sandra E. Black, Kuncheng Li, Takeshi Iwatsubo, Chiung Chih Chang, Ana Luisa Sosa, Christopher C. Rowe, Richard J. Perrin, John C. Morris, Amanda M.B. HealanStephen E. Hall, Michael W. Weiner

Research output: Contribution to journalArticlepeer-review


The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public-private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI-1, ADNI-GO, ADNI-2, and ADNI-3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW-ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW-ADNI researchers who shared updates from ADNI-3 and their vision for ADNI-4.

Original languageEnglish (US)
Article numbere12226
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Issue number1
StatePublished - 2021


  • Alzheimer's disease
  • MRI
  • PET
  • Tau
  • amyloid
  • biomarkers
  • cerebrospinal fluid
  • cognitive impairment
  • neuroimaging

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives'. Together they form a unique fingerprint.

Cite this